News

Gladstone in the News January 8, 2026

Ex-Intel AI CTO Launches Topos Bio with $10.5M to Tackle ‘Undruggable’ Proteins Driving Alzheimer’s and Cancer

The AI Journal—A collaboration between Topos Bio and the team led by Steve Finkbeiner, director of the Center for Systems and Therapeutics at Gladstone, aims to apply a new approach to neurodegenerative disease.

Gladstone Experts Alzheimer’s Disease Neurological Disease Finkbeiner Lab

Article December 15, 2025

Gladstone’s Scientific Highlights of 2025

From fundamental insights to translational advances, here’s how Gladstone researchers moved science forward in 2025.

Gladstone Experts Alzheimer’s Disease Autoimmune Diseases COVID-19 Neurological Disease Genomic Immunology Cardiovascular Disease Data Science and Biotechnology Infectious Disease Conklin Lab

Video October 15, 2025

Science in Seconds | The Thinking Microscope: Research Powered by an AI Brain

In this video, Steve Finkbeiner and Jeremy Linsley showcase Gladstone’s groundbreaking “thinking microscope”—an AI-powered system that can design, conduct, and analyze experiments autonomously to uncover new insights into diseases like Alzheimer’s, Parkinson’s, and ALS.

Gladstone Experts ALS Alzheimer’s Disease Parkinson’s Disease Neurological Disease Finkbeiner Lab AI Big Data

Article October 6, 2025

Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research

Akassoglou has opened doors to understanding how the blood protein fibrin is involved in Alzheimer’s and other neurodegenerative diseases.

Awards News Release Alzheimer’s Disease Center for Neurovascular Brain Immunology Akassoglou Lab

Article August 25, 2025

Meet Gladstone: Oscar Yip

Oscar Yip is advancing Alzheimer’s research in Yadong Huang’s lab at Gladstone while drawing inspiration from his family, community, and his broader goal of helping patients.

Graduate Students and Postdocs Profile Alzheimer’s Disease

Gladstone in the News July 28, 2025

Gladstone Institutes Develops AI-Powered Thinking Microscope

ABC7 News—Steve Finkbeiner, director of the Center for Systems and Therapeutics at Gladstone, describes the revolutionary thinking microscope that his team developed to help identify better treatments for diseases like Alzheimer’s, Parkinson’s, and ALS.

Gladstone Experts ALS Alzheimer’s Disease Parkinson’s Disease Center for Systems and Therapeutics Finkbeiner Lab

Article July 28, 2025

Blood Vessels and Immune Cells Drive Risk for Alzheimer’s and Stroke

Gladstone scientists show that known genetic risk factors for neurological diseases act in the brain’s blood vessels and immune cells, revealing new targets for therapies.

News Release Research (Publication) Alzheimer’s Disease Neurological Disease Corces Lab Pollard Lab Yang Lab

Gladstone in the News July 21, 2025

Two Cancer Drugs Show Surprising Promise in Treating Alzheimer’s

Discover Magazine—With so few Alzheimer’s drugs available, repurposing medications approved for other conditions could be the key to tackling this complex disease. In fact, Gladstone Investigator Yadong Huang and his colleagues at UCSF discovered that a combination of two cancer drugs could reduce brain degeneration and restore memory, pointing toward a potent treatment path never considered before.

Gladstone Experts Alzheimer’s Disease Huang Lab

Gladstone in the News July 21, 2025

Could Cancer Drugs Be the Future of Alzheimer’s Treatment?

NBC News—Gladstone Investigator Yadong Huang comments on a new study he helped lead, in which two cancer drugs showed signs of slowing or reversing symptoms of Alzheimer’s disease.

Gladstone Experts Alzheimer’s Disease Huang Lab

Article July 21, 2025

Inside the Brain: Tackling Neurological Disease at Its Roots

For World Brain Day, discover some of Gladstone’s latest breakthroughs in neurological research.

Gladstone Experts Research (Publication) Alzheimer’s Disease COVID-19 Parkinson’s Disease Neurological Disease Akassoglou Lab Corces Lab Huang Lab Mucke Lab

Article July 21, 2025

Combination of Two Cancer Drugs May Work Against Alzheimer’s

A new study has identified FDA-approved cancer drugs that reverse the gene expression signatures associated with Alzheimer’s.

News Release Research (Publication) Alzheimer’s Disease Neurological Disease Huang Lab

Article May 13, 2025

Zhaoqi Yan Named a 2025 Warren Alpert Distinguished Scholar

Gladstone researcher receives prize to study blood-brain barrier dysfunction and its impact on neurological disease.

Awards News Release Alzheimer’s Disease Neurological Disease Akassoglou Lab

Gladstone in the News April 25, 2025

Could a Virus Trigger Alzheimer’s Disease?

AARP—Lennart Mucke, director of the Gladstone Institute of Neurological Disease, does not think that viruses cause Alzheimer's disease, but suggests that they may act as environmental triggers that interact with genetic factors to contribute to disease.

Gladstone Experts Alzheimer’s Disease Neurological Disease Mucke Lab

Gladstone in the News April 16, 2025

The Unusual Genetic Inheritance That Could Change Alzheimer’s Treatment

Nature—In the 1980s, scientists began studying a family that suffered a genetic form of early-onset Alzheimer’s disease. Three decades later, they identified one member of that family who showed remarkable protection against the cognitive decline of Alzheimer’s due to a rare mutation in the ApoE gene. Now, Gladstone Senior Investigator Yadong Huang and others are working to develop therapies that mimic that protective mutation, hoping to treat or even prevent Alzheimer’s disease.

Gladstone Experts Alzheimer’s Disease Huang Lab

Gladstone in the News November 26, 2024

AI Reveals Alzheimer’s Subtle, Invisible Warning Signs

StudyFinds—Scientists in Jorge Palop’s lab have developed a cutting-edge technology that could transform how we identify Alzheimer’s years before traditional symptoms become obvious.

Gladstone Experts Alzheimer’s Disease Neurological Disease Palop Lab